Cantor Fitzgerald Maintains Overweight on Innoviva, Lowers Price Target to $34
Cantor Fitzgerald analyst Steve Seedhouse maintains Innoviva (NASDAQ:INVA) with a Overweight and lowers the price target from $36 to $34.
Stocks · News reference
Innoviva Q2 EPS $(1.14) Misses $0.40 Estimate, Sales $119.600M Beat $110.985M Estimate
Innoviva (NASDAQ:INVA) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $0.40 by 385 percent. This is a 248.05 percent decrease over earnings of $0.77 per share from the same
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Innoviva, Inc. (INVA)
Filed: 2026-08-05 AccNo: 0001193125-26-335192 Size: 257 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Nortiva Bio Launches Clinical-Stage Biopharmaceutical Company To Develop Long-Acting Oral Medicines